Publicación:
COVID-19, más allá de la enfermedad

Vista sencilla de ítem
dc.contributor.authorAlzate Cuevas, Yuri Valeriaspa
dc.contributor.authorÁlvarez-Sánchez1, Andrea del Pilarspa
dc.contributor.authorBejarano Avendano, Laura Alejandraspa
dc.contributor.authorMéndez Rodríguez3, Iván Albertospa
dc.date.accessioned2025-07-21T07:12:32Z
dc.date.accessioned2025-08-05T14:25:35Z
dc.date.available2025-07-21T07:12:32Z
dc.date.available2025-08-05T14:25:35Z
dc.date.issued2025-07-21
dc.description.abstractAntecedentes: Desde el primer caso reportado de la COVID-19, enfermedad causada por el virus SARS-CoV-2, caracterizada por una presentación clínica variable cuyas principales manifestaciones son las respiratorias, generó un impacto no solo en la salud pública, sino también en los distintos campos que abarca la ciencia moderna, representando un reto para la investigación. Razón por la cual la presente revisión intenta sintetizar la información relevante acerca de la etiología, fisiopatología, clínica, diagnóstico y tratamiento de esta novedosa enfermedad; teniendo en cuenta el proceso dinámico de información el cual se actualiza en algunos aspectos de manera periódicaspa
dc.description.abstractBackground: Since the first case reported of COVID-19, disease caused by the SARS-CoV-2, has been characterized by a variable clinic presentation whose main manifestations are the respiratory ones, it created an impact not just in public health, but also in the different fields of modern science, representing a challenge for research. For this reason, the present review tries to synthesize the relevant information about the etiology, physiopathology, clinic presentation, diagnostic and treatment of this novel disease; taking into account the dynamic process of information which is updated in some aspects periodically.eng
dc.format.mimetypeapplication/pdfspa
dc.identifier.doi10.26752/cuarzo.v30.n1.664
dc.identifier.eissn2500-7181
dc.identifier.issn0121-2133
dc.identifier.urihttps://repositorio.juanncorpas.edu.co/handle/001/449
dc.identifier.urlhttps://doi.org/10.26752/cuarzo.v30.n1.664
dc.language.isospaspa
dc.publisherFundación Universitaria Juan N. Corpasspa
dc.relation.bitstreamhttps://revistas.juanncorpas.edu.co/index.php/cuarzo/article/download/664/554
dc.relation.citationendpage25
dc.relation.citationissue1spa
dc.relation.citationstartpage14
dc.relation.citationvolume30spa
dc.relation.ispartofjournalRevista Cuarzospa
dc.relation.referencesAhn DG, Shin HJ, Kim MH, Lee S, Kim HS, Myoung J, et al. Current status of epidemiology, diagnosis, therapeutics, and vaccines for novel coronavirus disease 2019 (COVID-19). J Microbiol Biotechnol. 2020;30(3):313–24. DOI: 10.4014/jmb.2003.03011spa
dc.relation.referencesPalacios Cruz M, Santos E, Velázquez Cervantes MA, León Juárez M. COVID-19, una emergencia de salud pública mundial. Rev Clínica Española. 2021;221(1):55–61. DOI: 10.1016/j.rce.2020.03.001spa
dc.relation.referencesDhama K, Khan S, Tiwari R, Sircar S, Bhat S, Malik YS, et al. Coronavirus Disease 2019 -COVID-19. Clin Microbiol Rev [Internet]. 2020;33(4):1–48. Available from: DOI: https://doi.org/10.1128/CMR.00028-20spa
dc.relation.referencesHarapan H, Itoh N, Yufika A, Winardi W, Keam S, Te H, et al. Coronavirus disease 2019 (COVID-19): A literature review. J Infect Public Health. 2020;13(5):667–73. DOI: 10.1016/j.jiph.2020.03.019spa
dc.relation.referencesCentros para el Control y la prevención de Enfermedades. Sindrome respiratorio agudo severo. C.D.F. 2004. https://www.cdc.gov/sars/index-sp.htmlspa
dc.relation.referencesYang Y, Xiao Z, Ye K, He X, Sun B, Qin Z, et al. SARS-CoV-2: characteristics and current advances in research. Virol J. 2020;17(1):1–17. DOI: https://doi.org/10.1186/s12985-020-01369-zspa
dc.relation.referencesPetersen E, Koopmans M, Go U, Hamer DH, Petrosillo N, Castelli F, et al. Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics. Lancet Infect Dis. 2020;20(9):e238–44. DOI: 10.1016/S1473-3099(20)30484-9.spa
dc.relation.referencesDíaz-Castrillón FJ, Toro-Montoya AI. SARS-CoV-2/COVID-19: el virus, la enfermedad y la pandemia. Med y Lab. 2020;24(3):183–205. DOI: https://doi.org/10.36384/01232576.268spa
dc.relation.referencesJosé FG, González JGÁ, Molina JMC, Arnau LB, Iribarren IM, Jabaloyas JMM, et al. SARS-CoV-2 infection: implications for sexual and reproductive health. A position statement of the Asociación Española de Andrología, Medicina Sexual y Reproductiva (ASESA). Rev Int Androl. 2020;18(3):117–23. DOI: 10.1016/j.androl.2020.06.001.spa
dc.relation.referencesYuki K et al. Review Article COVID-19 pathophysiology: A review. Clin Immunol [Internet]. 2020;215(January):1–8. DOI https://doi.org/10.1016/j.clim.2020.108427spa
dc.relation.referencesChan JFW, Kok KH, Zhu Z, Chu H, To KKW, Yuan S, et al. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg Microbes Infect. 2020;9(1):221–36. DOI: 10.1080/22221751.2020.1719902spa
dc.relation.referencesWorld Health Organization. WHO Coronavirus Disease (COVID-19) Dashboard [Internet]. 2021. Available from: https://covid19.who.intspa
dc.relation.referencesSocial M de S y P. Colombia confirma su primer caso de COVID-19 [Internet]. Boletin de prensa No. 050 de 2020. 2020. Available from: https://www.minsalud.gov.co/Paginas/Colombia-confirma-su-primer-caso-de-COVID-19.aspxspa
dc.relation.referencesToledo JD, Bernal C, Ramírez B, Rodríguez S, Vallejo M, Rivera D, et al. SEGUIMIENTO COVID-19 COLOMBIA 30 -SEPTIEMBRE-2020 Dia 206 del Brote en Colombia. Bogotá D.C; 2020.Fuente: Comunicación personal.spa
dc.relation.referencesOrganización Panamericana de la Salud. Indicadores incidencia y Gravedad Actualización situación COVID-19 Colombia. Inst Nac Salud, Obs Nac Salud. 2020;(151):1–9. https://www.paho.org/es/reportes-situacion-covid-19-colombiaspa
dc.relation.referencesOrganización Panamericana de la Salud. Reporte de Situacion COVID-19 Colombia No. 206 - 02 de febrero 2021 Indicadores de incidencia. Colombia; 2020. https://www.paho.org/es/reportes-situacion-covid-19-colombiaspa
dc.relation.referencesCare E point of. Coronavirus: novel coronavirus (COVID-19) infection. Elsevier. 2020. p. 1–46. https://www.elsevier.com/__data/assets/pdf_file/0011/990722/Coronavirus-novel-coronavirus-COVID-19-infection-CO-200520.pdfspa
dc.relation.referencesDu Y, Tu L, Zhu P, Mu M, Wang R, Yang P, et al. Clinical features of 85 fatal cases of COVID-19 from Wuhan: A retrospective observational study. Am J Respir Crit Care Med. 2020;201(11):1372–9. DOI: 10.1164/rccm.202003-0543OCspa
dc.relation.referencesThapa K, Mph B, Badal S, Bajgain BB, Santana MJ. Prevalence of comorbidities among individuals with COVID-19: A rapid review of current literature. Am J Infect Control. 2020;49(January):238–46. DOI: 10.1016/j.ajic.2020.06.213spa
dc.relation.referencesZhai P, Ding Y, Wu X, Long J, Zhong Y, Li Y. The epidemiology, diagnosis, and treatment of COVID-19. J Antimicrob agents. 2020;55(January):1–13. DOI: 10.1016/j.ijantimicag.2020.105955spa
dc.relation.referencesBacker JA, Klinkenberg D, Wallinga J. Incubation period of 2019 novel coronavirus (2019- nCoV) infections among travellers from Wuhan, China, 20 28 January 2020. Eurosurveillance. 2020;25(5):1–6. DOI: 10.2807/1560-7917.ES.2020.25.5.2000062spa
dc.relation.referencesHarrison AG, Lin T, Wang P. Mechanisms of SARS-CoV-2 Transmission and Pathogenesis. Trends Immunol. 2020;41(12):1100–15. DOI: 10.1016/j.it.2020.10.004spa
dc.relation.referencesYe Q, Wang B, Mao J. The pathogenesis and treatment of the ‘Cytokine Storm’ in COVID-19. J Infect. 2020;80(January):607–13. DOI 10.1016/j.jinf.2020.03.037spa
dc.relation.referencesAlves A, Quispe A, Ávila A, Valdivia A, Chino J, Vera O. Breve historia y fisiopatologia del COVID-19. Guia Diagnostico y Trat COVID-19 en Unidades Ter Intensiva para Boliv. 2020;61(1):77–86. https://pesquisa.bvsalud.org/global-literature-on-novel-coronavirus-2019-ncov/resource/pt/covidwho-807138spa
dc.relation.referencesSalazar M, Barochiner J, Espeche W, Ennis I. COVID-19, hipertensión y enfermedad cardiovascular. Hipertens y riesgo Vasc. 2020;37(4):176–80. DOI: 10.1016/j.hipert.2020.06.003spa
dc.relation.referencesShibata S, Arima H, Asayama K, Hoshide S, Ichihara A, Ishimitsu T, et al. Hypertension and related diseases in the era of COVID-19: a report from the Japanese Society of Hypertension Task Force on COVID-19. Hypertens Res. 2020;43(10):1028–46. DOI: 10.1038/s41440-020-0515-0spa
dc.relation.referencesKanwal A, Agarwala A, Warsinger Martin L, Handberg EM, Yang E. COVID-19 and Hypertension: What We Know and Don’t Know [Internet]. 2020. Available from: https://www.acc.org/latest-in-cardiology/articles/2020/07/06/08/15/covid-19-and-hypertensionspa
dc.relation.referencesLippi G, Wong J, Henry BM. Hypertension in patients with coronavirus disease 2019 (COVID-19): A pooled analysis. Polish Arch Intern Med. 2020;130(4):304–9. DOI: 10.20452/pamw.15272spa
dc.relation.referencesGuan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020;382(18):1708–20. DOI: 10.1016/j.jemermed.2020.04.004spa
dc.relation.referencesPascarella G, Strumia A, Piliego C, Bruno F, Del Buono R, Costa F, et al. COVID-19 diagnosis and management: a comprehensive review. J Intern Med. 2020;288(2):192–206. DOI: 10.1111/joim.13091spa
dc.relation.referencesRodriguez-Morales AJ, Cardona-Ospina JA, Gutiérrez-Ocampo E, Villamizar-Peña R, Holguin-Rivera Y, Escalera-Antezana JP, et al. Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis. Travel Med Infect Dis. 2020;34(March):101623. DOI: 10.1016/j.tmaid.2020.101623spa
dc.relation.referencesLi YC, Bai WZ, Hashikawa T. The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients. J Med Virol. 2020;92(6):552–5. DOI: 10.1002/jmv.25728spa
dc.relation.referencesTong JY, Wong A, Zhu D, Fastenberg JH, Tham T. The Prevalence of Olfactory and Gustatory Dysfunction in COVID-19 Patients: A Systematic Review and Meta-analysis. Otolaryngol - Head Neck Surg (United States). 2020;163(1):3–11. DOI: 10.1177/0194599820926473spa
dc.relation.referencesRecalcati S. Cutaneous manifestations in COVID-19: a first perspective. J Eur Acad Dermatology Venereol. 2020;34(5):e212–3. DOI: 10.1111/jdv.16387spa
dc.relation.referencesYan Z, Wei C, Meng X, Yuanjie L, Yang Y, Jing Z, et al. Clinical and coagulation characteristics of 7 patients with critical COVID-19 pneumonia and acro-ischemia. Chinese J Hematol [Internet]. 2020;41(04):302–7. Available from: DOI: 10.3760/cma.j.issn.0253-2727.2020.008spa
dc.relation.referencesManalo IF, Smith MK, Cheeley J, Jacobs R. A dermatologic manifestation of COVID-19: Transient livedo reticularis. J Am Acad Dermatol. 2020;83(2):700. DOI: 10.1016/j.jaad.2020.04.018spa
dc.relation.referencesOMS. Síndrome inflamatorio multisistémico en niños y adolescentes con COVID-19. Inf científico. 2020;1–3. WHO reference number: WHO/2019-nCoV/Sci_Brief/Multisystem_Syndrome_Children/2020.1spa
dc.relation.referencesOrganización Panamericana de la Salud / Organización Mundial de la Salud. Alerta Epidemiológica complicaciones y secuelas por. Ops/Oms. 2020; https://www.paho.org/es/documentos/alerta-epidemiologica-complicaciones-secuelas-por-covid-19-12-agosto-2020spa
dc.relation.referencesGrupo ACIN. Consenso Colombiano de atención, diagnóstico y manejo de la infección por SARS-CoV-2/COVID-19 en establecimientos de atención de la salud. INFECTIO [Internet]. 2020;24(3):14–24. Available from: http://www.iets.org.co/Archivos/853-2765-1-PB.pdfspa
dc.relation.referencesSalehi S, Abedi A, Balakrishnan S, Gholamrezanezhad A. Coronavirus disease 2019 (COVID-19): A systematic review of imaging findings in 919 patients. Am J Roentgenol. 2020;215(1):87–93. doi: 10.2214/AJR.20.23034spa
dc.relation.referencesHuang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. DOI: 10.1016/S0140-6736(20)30183-5spa
dc.relation.referencesJin YH, Cai L, Cheng ZS, Cheng H, Deng T, Fan YP, et al. A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version). Med J Chinese People’s Lib Army. 2020;45(1):1–20. DOI: 10.1186/s40779-020-0233-6spa
dc.relation.referencesCheng VC, Edwards KM, Gandhi R, Muller WJ. Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19. IDSA. 2020. DOI: 10.1093/cid/ciaa478spa
dc.relation.referencesLin L, Lu L, Cao W, Li T. Hypothesis for potential pathogenesis of SARS-CoV-2 infection–a review of immune changes in patients with viral pneumonia. Emerg Microbes Infect. 2020;9(1):727–32. DOI: 10.1080/22221751.2020.1746199 45. Kalil AC, Patterson TF, Mehta AK, Tomashek KM, Wolfe CR, Ghazaryan V, et al. Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19. N Engl J Med. 2020;1–13. DOI : 10.1056/NEJMoa2031994spa
dc.relation.referencesFood and drug administration. Coronavirus (COVID-19) Update: FDA Authorizes Monoclonal Antibody for Treatment of COVID-19 [Internet]. 2020. Available from: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-monoclonal-antibody-treatment-covid-19spa
dc.relation.referencesJackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, et al. An mRNA Vaccine against SARS-CoV-2 — Preliminary Report. N Engl J Med. 2020;383(20):1920–31. DOI: 10.1056/NEJMoa2022483spa
dc.relation.referencesPfizer. PFIZER AND BIONTECH ACHIEVE FIRST AUTHORIZATION IN THE WORLD FOR A VACCINE TO COMBAT COVID-19 [Internet]. 2020. Available from: https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-achieve-first-authorization-worldspa
dc.relation.referencesPfizer. PFIZER AND BIONTECH ANNOUNCE PUBLICATION OF RESULTS FROM LANDMARK PHASE 3 TRIAL OF BNT162B2 COVID-19 VACCINE CANDIDATE IN THE NEW ENGLAND JOURNAL OF MEDICINE [Internet]. 2020. Available from: https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-publication-results-landmarkspa
dc.relation.referencesRandall T, Sam C, Tartar A, Murray P, Cannon C. COVID 19 vaccine tracker global distribution [Internet]. 2021. Available from: https://www.bloomberg.com/graphics/covid-vaccine-tracker-global-distribution/spa
dc.relation.referencesWHO. Status of COVID-19 Vaccines within WHO EUL / PQ evaluation process. Who. 2021;26(December 2020):2020–2.spa
dc.relation.references(FDA) TU. F and DA. EMERGENCY USE AUTHORIZATION (EUA) OF THE PFIZER-BIONTECH COVID-19 VACCINE TO PREVENT CORONAVIRUS DISEASE 2019 (COVID-19). 2021. p. 1–30. Available from: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-pfizer-biontech-covid-19-vaccine-emergency-usespa
dc.relation.referencesCentros para el Control y la prevención de Enfermedades. Pfizer-BioNTech [Internet]. 2021 [cited 2021 Feb 6]. Available from: https://espanol.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/Pfizer-BioNTech.htmlspa
dc.relation.referencesZhang Y, Zeng G, Pan H, Li C, Hu Y, Chu K, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021;21(2):181–92. DOI: 10.1016/S1473-3099(20)30843-4spa
dc.relation.referencesBischler A. Dosing information for AstraZeneca COVID-19 Vaccine [Internet]. 13 January. 2021 [cited 2021 Feb 5]. Available from: https://www.sps.nhs.uk/articles/dosing-information-for-astrazeneca-covid-19-vaccine/spa
dc.relation.referencesAstraZeneca. COVID-19 Vaccine AstraZeneca confirms 100% protection against severe disease, hospitalisation and death in the primary analysis of Phase III trials [Internet]. 3 February. 2021 [cited 2021 Feb 5]. Available from: https://www.astrazeneca.com/media-centre/press-releases/2021/covid-19-vaccine-astrazeneca-confirms-protection-against-severe-disease-hospitalisation-and-death-in-the-primary-analysis-of-phase-iii-trials.htmlspa
dc.relation.referencesProducts M& H, Regulatory Agency. Information for Healthcare Professionals on COVID- 19 Vaccine AstraZeneca. 2021. p. 1–14. https://www.gov.uk/government/publications/regulatory-approval-of-covid-19-vaccine-astrazeneca/information-for-healthcare-professionals-on-covid-19-vaccine-astrazeneca-regulation-174spa
dc.relation.referencesInstituto de Efectividad Clínica y Sanitaria (IECS). Vacunas contra COVID-19 2. 2020. p. 1–18. Avaible at: https://docs.bvsalud.org/biblioref/2020/12/1140939/iecs-irr-814-va-1-3.pdfspa
dc.relation.referencesNational Institutes of Health. Janssen Investigational COVID-19 Vaccine: Interim Analysis of Phase 3 Clinical Data Released [Internet]. January 29. 2021. Available from: https://www.nih.gov/news-events/news-releases/janssen-investigational-covid-19-vaccine-interim-analysis-phase-3-clinical-data-releasedspa
dc.relation.referencesLevine H. COVID-19 Update: Your Latest Questions About Johnson & Johnson’s Investigational Vaccine Candidate Answered [Internet]. 2021 [cited 2021 Feb 5]. Available from: https://www.jnj.com/innovation/questions-about-johnson-johnson-investigational-covid-19-vaccinespa
dc.relation.referencesBatres O. Vacuna Covid Janssen: la dosis única genera anticuerpos en el 90% de casos [Internet]. Redacción médica. 2021 [cited 2021 Feb 5]. Available from: https://www.redaccionmedica.com/secciones/sanidad-hoy/vacuna-covid-janssen-dosis-unica-anticuerpos-5331spa
dc.relation.referencesBranswell H. Comparing the Covid-19 vaccines developed by Pfizer, Moderna, and Johnson & Johnson [Internet]. STAT. 2021 [cited 2021 Feb 5]. Available from: https://www.statnews.com/2021/02/02/comparing-the-covid-19-vaccines-developed-by-pfizer-moderna-and-johnson-johnson/spa
dc.relation.referencesMicrobiology TGNC of E and. Sputnik V, The first registered COVID-19 vaccine proven human adenoviral vector technology [Internet]. 2021 [cited 2021 Feb 17]. Available from: https://sputnikvaccine.com/esp/about-vaccine/spa
dc.relation.referencesMinisterio de Salud de Argentina. Campaña Nacional de Vacunación contra la COVID-19. 2o informe de vigilancia de seguridad de vacunas. [Internet]. 2021 [cited 2021 Feb 17]. Available from: https://www.fundacionfemeba.org.ar/blog/farmacologia-7/post/efectos-adversos-de-la-vacuna-sputnik-v-48739spa
dc.rightsYuri Valeria Alzate Cuevas, Andrea del Pilar Álvarez-Sánchez1, Laura Alejandra Bejarano Avendano, Iván Alberto Méndez Rodríguez3 - 2025spa
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.rights.coarhttp://purl.org/coar/access_right/c_abf2spa
dc.rights.creativecommonsEsta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial 4.0.spa
dc.rights.urihttps://creativecommons.org/licenses/by-nc/4.0spa
dc.sourcehttps://revistas.juanncorpas.edu.co/index.php/cuarzo/article/view/664spa
dc.subjectCovid-19eng
dc.subjectGlobal Healtheng
dc.subjectCoronaviruseng
dc.subjectCOVID-19spa
dc.subjectCoronavirusspa
dc.subjectSalud Globalspa
dc.titleCOVID-19, más allá de la enfermedadspa
dc.title.translatedCOVID-19, beyond the disease?eng
dc.typeArtículo de revistaspa
dc.type.coarhttp://purl.org/coar/resource_type/c_6501spa
dc.type.coarhttp://purl.org/coar/resource_type/c_dcae04bcspa
dc.type.coarversionhttp://purl.org/coar/version/c_970fb48d4fbd8a85spa
dc.type.contentTextspa
dc.type.driverinfo:eu-repo/semantics/articlespa
dc.type.localJournal articleeng
dc.type.redcolhttp://purl.org/redcol/resource_type/ARTREVspa
dc.type.versioninfo:eu-repo/semantics/publishedVersionspa
dspace.entity.typePublicationspa

Archivos

Colecciones

AMA. Revista Cuarzo